Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $15.00 → $13.00 | Outperform | Cowen & Co. |
Cantor Fitzgerald analyst Brandon Folkes reiterates Aziyo Biologics (NASDAQ:AZYO) with a Overweight and maintains $8 price target.
– Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket
SC 13G - ELUTIA INC. (0001708527) (Subject)
SC 13G/A - ELUTIA INC. (0001708527) (Subject)
SC 13D/A - ELUTIA INC. (0001708527) (Subject)
424B3 - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
S-8 - ELUTIA INC. (0001708527) (Filer)
SILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. "David's impressive commercial expertise was vital in guiding some of the world's largest and most-well respected biopharmaceutical companies in achieving their growth milestones," said Dr. Randy Mills, Chief Executive Officer of Aziyo Biologics. "We specifically sought a Board member, like David, whose deep industry insights and busi
SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. "Aziyo strives to have the best products in the markets in which we choose to compete, and Dr. Williams has the expertise and leadership to help us deliver just that," said Dr. Randy Mills, Chief Executive Officer. "Michelle has been a thought leader in regenerative medicine for two decades. She has a track record of consistently developing commercially successful products, including Osteocel®, the world's first stem cell product with cumulative sales of
SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. "We are delighted to welcome such a strong and experienced leader as Peter to our executive team," said Ron Lloyd, President and Chief Executive Officer of Aziyo. "We expect his deep experience serving as general counsel to high growth companies, particularly in the healthcare sector, will prove to be invaluable as we head into our next phase of growth. We have
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. "Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID:
- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Business Highlights: Net sales rose 14% compared to the prior-year period, to a record $13.1 million for first quarter 2023.Gross margin increased 11 percentage points year-over-year to 49%.Signed a partnership with LeMaitre Vascular to distribute Aziyo'
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company's Events & Presentations webpage or by clicking here. A replay will be available on the Company's website following the event. Institutional investors interested in meeting with management during the conference may reach out
– Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled "Rehabilitation of an Existing Device Implant Pocket Using a Biolog
Cowen & Co. reiterated coverage of Aziyo Biologics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously